Statistik Asas
| CIK | 1320350 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LENSAR, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, IN |
|
| August 7, 2025 |
Exhibit 99.1 LENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla. (August |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 2, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 22, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 19, 2025 |
DEFM14A 1 d920080ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 8, 2025 |
Exhibit 99.1 LENSAR Reports First Quarter 2025 Results and Provides Business Update 14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over t |
|
| May 8, 2025 |
Exhibit 99.1 LENSAR Reports First Quarter 2025 Results and Provides Business Update 14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over t |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| May 7, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) LENSAR, Inc. |
|
| May 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001- |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party Other than the Registrant ☒ Check the Appropriate Box ☐ Preliminary Proxy Statement ☐ Confidential for Use of the Commission only (as permitted by Rule 14a-6(e)(2)). |
|
| March 24, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| March 24, 2025 |
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG EX-99.1 Exhibit 99.1 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Alcon Agrees to Acquire LENSAR, Inc. • Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio • Next generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA, Switzerland and ORLANDO, FL March, 24, 2025 – Alcon (SIX/NY |
|
| March 24, 2025 |
EX-99.2 Exhibit 99.2 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of March 23, 2025, is entered into by and among Alcon Research, LLC, a Delaware limited liability company (“Parent”), and the stockholder of LENSAR, Inc., a Delaware corporation (the “Company”), listed on the signature page attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Parent a |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 24, 2025 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ALCON RESEARCH, LLC, VMI OPTION MERGER SUB, INC., and LENSAR, INC. dated as of March 23, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 3 1.1 The Merger 3 1.2 Effective Time 3 1.3 Closing 3 1.4 Organizational Documents of Surviving Corporation 3 1.5 Officers 4 1.6 Board of Directors 4 ARTICLE II EFFECT OF THE MERGER ON CAPITAL STOCK; E |
|
| February 28, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) LENSAR, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Plan Security Type Security Class Title Fee Recalculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2020 Incentive Award Plan E |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 99.1 LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update 31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. ( |
|
| February 27, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 LENSAR, Inc. Insider Trading Compliance Policy LENSAR, Inc. (the “Company”) seeks to promote a culture that encourages ethical conduct and a commitment to compliance with the law. We require our personnel to comply at all times with federal laws and regulations governing insider trading. This policy sets forth procedures designed to promote compliance with these laws and regulations. |
|
| February 27, 2025 |
Exhibit 10.18 INDUSTRIAL REAL ESTATE LEASE DISCOVERY TECH CENTER ORLANDO, FLORIDA by and between CHALLENGER-DISCOVERY, LLC, Landlord and LENSAR, INC., Tenant July 30, 2010 TABLE OF CONTENTS ARTICLE PAGE Article 1 BASIC TERMS 1 Article 2 PREMISES 3 ARTICLE 3 LEASE TERM 3 Article 4 REnt 4 Article 5 PROPERTY TAXES 6 article 6 utilities 6 Article 7 INSURANCE 7 Article 8 COMMON AREAS 10 Article 9 USE O |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 14, 2024 |
LNSR / LENSAR, Inc. / Park West Asset Management LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* LENSAR, inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 52634L108 (CUSIP Number) SEPTEMBER 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 7, 2024 |
Amended and Restated Bylaws of LENSAR, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LENSAR, INC. (a Delaware corporation) as of November 5, 2024 | Table of Contents Page Article I Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 1 2.5 Notice of Nominations for Electi |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSA |
|
| November 7, 2024 |
Exhibit 99.1 LENSAR Reports Third Quarter 2024 Results and Provides Business Update 24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, IN |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2024 |
Exhibit 99.1 LENSAR Reports Second Quarter 2024 Results and Provides Business Update 17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide |
|
| May 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Exhibit 10.3 LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice – DIRECTOR DEFERRAL Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company hereby grants to the participant |
|
| May 9, 2024 |
Form of Performance Stock Unit Agreement pursuant to 2020 Incentive Award Plan Exhibit 10.2 LENSAR, INC. 2020 INCENTIVE AWARD PLAN PERFORMANCe RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company hereby grants to the particip |
|
| May 9, 2024 |
Exhibit 99.1 LENSAR Reports First Quarter 2024 Results and Provides Business Update Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base to 65 systems ORLANDO, Fla. (May 9, 2024) – LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced |
|
| May 9, 2024 |
Non-Employee Director Compensation Program, as amended Exhibit 10.1 LENSAR, INC. Non-Employee DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective May 3, 2024) Non-employee members of the board of directors (the “Board”) of LENSAR, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2020 Incentive |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 03, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 5, 2024 As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. |
|
| March 5, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) LENSAR, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Plan Security Type Security Class Title Fee Recalculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2024 Employment Inducement |
|
| March 4, 2024 |
Description of Registered Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following is a description of the capital stock of LENSAR, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), our Second Amended and Restated Byl |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. ( |
|
| March 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 4, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 LENSAR, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION LENSAR, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy shall |
|
| March 4, 2024 |
Exhibit 99.1 LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update 44 ALLY® Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY installed base to 54 and a backlog of 9 additional systems as of December 31, 2023 Total revenue increased 18% in the fourth quarter and 19% over full year 2022 ORLANDO, Fla |
|
| February 26, 2024 |
Form of Stock Option Grant Notice pursuant to 2024 Employment Inducement Incentive Award Plan Exhibit 10.2 LENSAR, INC. 2024 EMPLOYMENT INDUCEMENT Incentive Award Plan Stock Option Grant Notice Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2024 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company hereby grants to the partic |
|
| February 26, 2024 |
Exhibit 10.3 LENSAR, INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2024 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company hereby gr |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 26, 2024 |
2024 Employment Inducement Incentive Award Plan Exhibit 10.1 LENSAR, INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTIC |
|
| February 14, 2024 |
LNSR / LENSAR, Inc. / Park West Asset Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LENSAR, inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 52634L108 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2024 |
LNSR / LENSAR, Inc. / CURTIS NICHOLAS T - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 52634L10 |
|
| February 9, 2024 |
LNSR / LENSAR, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* LENSAR Inc (Name of Issuer) Common Stock (Title of Class of Securities) 52634L108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 11, 2023 |
SC 13G/A 1 lensar13ga3-113023.htm AMENDMENT NO. 3 TO THE SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Sec |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSA |
|
| November 9, 2023 |
Exhibit 99.1 LENSAR Reports Third Quarter 2023 Results and Provides Business Update Increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023 Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022 ORLANDO, Fla. (November 8, 2023) – LENSAR, Inc. (Nasdaq: LN |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 11, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-272930 Prospectus LENSAR, Inc. UP TO 7,940,446 SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF SERIES A CONVERTIBLE PREFERRED STOCK, UP TO 2,183,623 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF CLASS A WARRANTS, AND UP TO 2,183,623 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF CLASS B WARRANTS OF LENSAR, INC. On May |
|
| August 9, 2023 |
Exhibit 99.1 LENSAR Reports Second Quarter 2023 Results and Provides Business Update Increased ALLY® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of June 30, 2023 U.S. procedure volumes increased 13% over second quarter 2022; 1H 2023 procedure volumes increased 15% year-over-year at sites that have upgraded from LENSAR L |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, IN |
|
| August 8, 2023 |
LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, Florida 32826 LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, Florida 32826 August 8, 2023 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Nicholas O’Leary & Katherine Bagley Re: LENSAR, Inc. Registration Statement on Form S-3 (Registration No. 333-272930) To the addressees set forth above: In a |
|
| August 4, 2023 |
650 Town Center Drive, 20th Floor 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris August 4, 2023 Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv VIA E |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| July 28, 2023 |
SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 = NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION) NAME OF REGISTRANT: LENSAR, Inc. NAME OF PERSON RELYING ON EXEMPTION: Ryan Schaper ADDRESS OF PERSON RELYING ON EXEMPTION: 3406 Via Lido Ste 1A 336, Newport Beach, California 92663 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act o |
|
| July 17, 2023 |
SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION) NAME OF REGISTRANT: LENSAR, Inc. NAME OF PERSON RELYING ON EXEMPTION: Ryan Schaper ADDRESS OF PERSON RELYING ON EXEMPTION: 3406 Via Lido Ste 1A 336, Newport Beach, California 92663 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of |
|
| June 26, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LENSAR, Inc. |
|
| June 26, 2023 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S |
|
| June 20, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| June 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy S |
|
| May 30, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 19, 2023 |
EX-99.5 Exhibit 99.5 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of LENSAR, Inc., a Delaware corporation. This Join |
|
| May 19, 2023 |
LNSR / LENSAR Inc / NORTH RUN CAPITAL, LP - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) LENSAR, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 52634L108 (CUSIP Number) Todd B. Hammer North Run Capital, LP 867 Boylston Street 5th Floor #1361 Boston, MA 02116 Robert A. Petitt, Esq. Burns & Levinson LLP |
|
| May 18, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF LENSAR, INC. LENSAR, Inc. (the “Company”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that, pursuant to authority conferred upon the Board of Directors of the Company by the Amended and Restated Certificate of In |
|
| May 18, 2023 |
Class B Common Stock Purchase Warrant, dated May 18, 2023 EX-4.2 Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMEN |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 18, 2023 |
Class A Common Stock Purchase Warrant, dated May 18, 2023 EX-4.1 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMEN |
|
| May 18, 2023 |
EX-10.1 Exhibit 10.1 FORM OF VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of May 18, 2023, is entered into by and between the undersigned stockholder (the “Stockholder”) of LENSAR, Inc., a Delaware corporation (the “Company”), and the Company. The Company and the Stockholder are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.” RE |
|
| May 15, 2023 |
Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF LENSAR, INC. LENSAR, Inc. (the “Company”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that, pursuant to authority conferred upon the Board of Directors of the Company by the Amended and Restated Certificate of In |
|
| May 15, 2023 |
Form of Common Stock Purchase Warrant EX-4.1 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMEN |
|
| May 15, 2023 |
Securities Purchase Agreement, dated May 12, 2023, between LENSAR, Inc. and NR-GRI Partners, LP EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 12, 2023, by and among LENSAR, Inc., a Delaware corporation (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). WHEREAS: A. The Company and the Buyers are executing and delivering this Agreement |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2023 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| May 15, 2023 |
Exhibit 99.1 LENSAR Reports First Quarter 2023 Results and Provides Business Update Increased ALLY® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded from LENSAR Laser System (LLS) to ALLY |
|
| May 15, 2023 |
Registration Rights Agreement, dated May 12, 2023, between LENSAR, Inc, and NR-GRI Partners, LP EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2023, by and between LENSAR, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purch |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 21, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 21, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) LENSAR, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Plan Security Type Security Class Title Fee Recalculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2020 Incentive Award Plan E |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. ( |
|
| March 16, 2023 |
Exhibit 99.1 LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Installed ten ALLY® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla. (March |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 14, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d461502dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th |
|
| February 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2023 |
LNSR / LENSAR, Inc. / Madison Avenue Partners, LP Passive Investment SC 13G/A 1 lensar13ga2-021423.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69329Y112 (CUSIP Number) De |
|
| February 14, 2023 |
LNSR / LENSAR, Inc. / Silver Point Capital L.P. - SC 13G/A Passive Investment SC 13G/A 1 d461502dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 52634L108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2023 |
Exhibit 99.1 LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results Installed ten ALLY® Adaptive Cataract Treatment Systems in 2022 Contracts for an additional six ALLY Systems executed in December 2022; Installations expected in first half 2023 ORLANDO, Fla. (February 14, 2023) – LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused o |
|
| February 13, 2023 |
LNSR / LENSAR, Inc. / NORTH RUN CAPITAL, LP - SC 13G/A Passive Investment SC 13G/A 1 d466563dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 LENSAR, Inc. (Name of Issuer) Common Stock, $0.01 par value (Tit |
|
| February 10, 2023 |
LNSR / LENSAR, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* LENSAR Inc (Name of Issuer) Common Stock (Title of Class of Securities) 52634L108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 8, 2023 |
LNSR / LENSAR, Inc. / CURTIS NICHOLAS T - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 9, 2022 |
Exhibit 99.1 LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update Company Launches ALLY™ Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 ORLANDO, Fla. (November 9, 2022) – LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions f |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSA |
|
| September 8, 2022 |
Exhibit 99.1 LENSAR Announces Application for Certification of the ALLY? Adaptive Cataract Treatment System in the EU ORLANDO, Fla. (September 8, 2022) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY? A |
|
| September 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 08, 2022 LENSAR, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 16, 2022 |
First Patients Treated with LENSAR’s® ALLY™ Adaptive Cataract Treatment System Exhibit 99.1 First Patients Treated with LENSAR?s? ALLY? Adaptive Cataract Treatment System August 16, 2022 ORLANDO, Fla.-(BUSINESS WIRE)- LENSAR, Inc. (NASDAQ: LNSR) (?LENSAR? or the ?Company?), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the first commercial cases performed with the ALLY? Adaptive Ca |
|
| August 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 9, 2022 |
Up to $18,615,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255136 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated April 15, 2021 To Prospectus dated April 15, 2021) Up to $18,615,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated April 15, 2021, filed with the Securities and Exchange Commission as a part of our registration statement on For |
|
| August 8, 2022 |
Exhibit 99.1 LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update Company Receives FDA Clearance of ALLY? Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels ORLANDO, Fla. (August 8, 2022) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical technology company |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, IN |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 27, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 9, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 13, 2022 |
LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System Exhibit 99.1 LENSAR? Receives U.S. FDA Clearance of ALLY? Adaptive Cataract Treatment System June 13, 2022, ORLANDO, Fla. LENSAR, Inc. (NASDAQ: LNSR) (?LENSAR? or the ?Company?), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration (?FDA?) 510(k) clearance for its next-generati |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2022 |
Exhibit 99.1 LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Revenue Increases 33% Over 2021 Levels First Quarter Procedure Volume Increases 38% Over 2021 Levels ORLANDO, Fla. (May 9, 2022) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical technology company focused on advanced femtosecond laser surgical solutions for the tre |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 12, 2022 |
DEFA14A 1 lnsr-defa14a20220525.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate b |
|
| March 4, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 4, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) LENSAR, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2020 Incentive Award Plan Equ |
|
| March 3, 2022 |
Exhibit 99.1 LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 2021 Revenue Increases $8.1 million or 31% over 2020 Levels Procedure Volume Increases over 2020 Levels by 37% in Fourth Quarter and by 35% in 2021 Cash and Cash Equivalents of $31.6 Million Reflect Cash Utilization of $0.7 Million in the Fourth Quarter ORLANDO, Fla. (March 3, 2022) ? LENSA |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exac |
|
| March 3, 2022 |
Form of Stock Option Agreement pursuant to 2020 Incentive Award Plan Exhibit 10.5 LENSAR, INC. 2020 Incentive Award Plan Stock Option Grant Notice Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the ?Plan?) of LENSAR, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Participant?) the stock |
|
| March 3, 2022 |
Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan Exhibit 10.6 LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the ?Plan?) of LENSAR, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Parti |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 3, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 3, 2022 |
Non-Employee Director Compensation Program, as amended Exhibit 10.15 LENSAR, INC. Non-Employee DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective January 11, 2022) Non-employee members of the board of directors (the ?Board?) of LENSAR, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2020 Ince |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 1, 2022 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69329Y112 (CUSIP Number) December 31, 2021 (Date of Event whi |
|
| February 14, 2022 |
LNSR / LENSAR, Inc. / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LENSAR, inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 52634L108 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
LNSR / LENSAR, Inc. / NORTH RUN CAPITAL, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. |
|
| February 8, 2022 |
LNSR / LENSAR, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* LENSAR Inc (Name of Issuer) Common Stock (Title of Class of Securities) 52634L108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2022 LENSAR, Inc. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSA |
|
| November 8, 2021 |
Exhibit 99.1 LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Quarter ORLANDO, Fla. (November 8, 2021) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical technology company focused on a |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 00 |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0 |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, IN |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 5, 2021 |
Exhibit 99.1 LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter ORLANDO, Fla. (August 5, 2021) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical |
|
| May 20, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-39473 32-0125724 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| May 6, 2021 |
Non-Employee Director Compensation Program (as amended) Exhibit 10.1 LENSAR, INC. Non-Employee DIRECTOR COMPENSATION PROGRAM (As Amended Effective March 12, 2021) Non-employee members of the board of directors (the ?Board?) of LENSAR, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2020 Incentive Award Plan |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2021 |
Exhibit 99.1 LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update First Quarter 2021 Procedure Volumes Increase 21.1% over First Quarter 2020 Cash and Cash Equivalents of $35.9 Million as of March 31, 2021 ORLANDO, Fla. (May 5, 2021) ? LENSAR, Inc. (Nasdaq: LNSR) (?LENSAR? or ?the Company?), a global medical technology company focused on advanced femtosecond laser surgi |
|
| April 15, 2021 |
Up to $35,000,000 COMMON STOCK Filed Pursuant to Rule 424(b)(5) Registration No. 333-255136 PROSPECTUS SUPPLEMENT (To prospectus dated April 15, 2021) Up to $35,000,000 COMMON STOCK We have entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, dated April 8, 2021, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In a |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 12, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 13, 2021 |
April 13, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 8, 2021 |
Sales Agreement, dated April 8, 2021, by and between LENSAR, Inc. and SVB Leerink LLC. Exhibit 1.2 LENSAR, Inc. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT April 8, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: LENSAR, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1.Issuance and Sale of Shares. The Company agre |
|
| April 8, 2021 |
Exhibit 4.3 LENSAR, INC. INDENTURE Dated as of, 20 Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishment of Te |
|
| April 8, 2021 |
As filed with the Securities and Exchange Commission on April 8, 2021 Registration No. |
|
| April 8, 2021 |
650 Town Center Drive, 20th Floor 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington |
|
| April 5, 2021 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 5, 2021 DEF 14A 1 nc10022726x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Ch |
|
| April 5, 2021 |
DEFA14A 1 nc10022726x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriat |
|
| March 12, 2021 |
Description of Registered Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, LENSAR, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to LENSAR, Inc. and not to any |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exac |
|
| March 12, 2021 |
Form of Stock Option Agreement pursuant to 2020 Incentive Award Plan Exhibit 10.5 LENSAR, INC. 2020 Incentive Award Plan Stock Option Grant Notice Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the ?Plan?) of LENSAR, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Participant?) the stock |
|
| March 12, 2021 |
Non-Employee Director Compensation Program, as amended Exhibit 10.14 LENSAR, INC. Non-Employee DIRECTOR COMPENSATION PROGRAM (As Amended Effective January 29, 2021) Non-employee members of the board of directors (the ?Board?) of LENSAR, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2020 Incentive Award P |
|
| March 12, 2021 |
Second Amended and Restated Bylaws of LENSAR, Inc Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF LENSAR, INC. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office1 1.2 Other Offices1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings1 2.2 Annual Meeting1 2.3 Special Meeting1 2.4 Advance Notice Procedures for Business Brought before a Meeting2 2.5 Advance Notice Procedures for Nominati |
|
| March 12, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE COMPANY The Company has no subsidiaries. |
|
| March 12, 2021 |
Amended and Restated Bylaws of LENSAR, Inc. (redlined version of amended section) Exhibit 3.3 SECOND AMENDED AND RESTATED BYLAWS OF LENSAR, INC. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office1 1.2 Other Offices1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings1 2.2 Annual Meeting1 2.3 Special Meeting1 2.4 Advance Notice Procedures for Business Brought before a Meeting2 2.5 Advance Notice Procedures for Nominati |
|
| March 10, 2021 |
Exhibit 99.1 LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Fourth Quarter 2020 Procedure Volumes Consistent with Fourth Quarter 2019 Levels Cash and Cash Equivalents of $40.6 Million as of December 31, 2020 ORLANDO, Fla. (March 10, 2021) – LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanc |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2021 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware001-03947332-0125724 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LENSAR, inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 52634L108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 52634L108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENSAR Inc (Name of Issuer) Common Stock (Title of Class of Securities) 52634L108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 11, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 52 |
|
| February 1, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2021 LENSAR, Inc. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or other jurisdiction of incorporation) (Commission File |
|
| February 1, 2021 |
EX-99.1 Exhibit 99.1 LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrell ORLANDO, Fla. (February 1, 2021) – LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the expansion of its Board of Directors to seven mem |
|
| December 11, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 7, 2020 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39473 LENSAR, I |
|
| November 9, 2020 |
EX-99.1 Exhibit 99.1 2800 DISCOVERY DRIVE ORLANDO, FL 32826 LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update Procedure Numbers Consistent with 2019 Levels Cash and Cash Equivalents of $42.7 Million as of September 30, 2020 ORLANDO, Fla. (November 9, 2020) – LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtos |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2020 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 01-039473 32-0125724 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 15, 2020 |
LNSR / LENSAR, Inc. / Silver Point Capital L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENSAR, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 52634L108 (CUSIP Number) October 7, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| October 13, 2020 |
LNSR / LENSAR, Inc. / Park West Asset Management LLC - INITIAL FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENSAR, inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 52634L108 (CUSIP Number) OCTOBER 1, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| October 13, 2020 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, par value $0. |
|
| October 5, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 5, 2020 Registration No. |
|
| October 5, 2020 |
Form of Restricted Stock Award Agreement pursuant to 2020 Incentive Award Plan EX-10.2 Exhibit 10.2 LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company has granted to the participant listed below (“Participa |
|
| October 5, 2020 |
EX-10.1 Exhibit 10.1 LENSAR, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| October 2, 2020 |
LENSAR, Inc. Begins Trading on NASDAQ EX-99.1 Exhibit 99.1 Contacts: Thomas R. Staab, II [email protected] LENSAR, Inc. Begins Trading on NASDAQ ORLANDO, Fl. (October 2, 2020) – LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the completion of its spin-off from PDL BioPharma, Inc. (NASDAQ: PD |
|
| October 2, 2020 |
Amended and Restated Certificate of Incorporation of LENSAR, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LENSAR, INC. LENSAR, INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is LENSAR, Inc. The Corporation was incorporated under the name LaserSoft Vision, Inc. by the filing of its |
|
| October 2, 2020 |
Separation and Distribution Agreement between PDL BioPharma, Inc. and LENSAR, Inc. EX-2.1 Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND LENSAR, INC. DATED AS OF SEPTEMBER 30, 2020 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 2 Section 1.1 General 2 Section 1.2 Reference; Interpretation 9 Section 1.3 Tax Matters 9 ARTICLE II. THE SEPARATION 10 Section 2.1 Restructuring 10 Section 2.2 Transfer of LENSAR Assets and LENSAR Business; Assumption |
|
| October 2, 2020 |
Amended and Restated Bylaws of LENSAR, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LENSAR, INC. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures for Business Brought before a Meeting 2 2.5 Advance Notice Procedures for No |
|
| October 2, 2020 |
Transition Services Agreement between PDL BioPharma, Inc. and LENSAR, Inc EX-10.1 Exhibit 10.1 TRANSITION SERVICES AGREEMENT THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2020, by and between PDL BioPharma, Inc., a Delaware corporation (“PDL”) and LENSAR, Inc., a Delaware corporation (“LENSAR”). PDL and LENSAR are referred to herein individually as a “Party”, and collectively as the “Parties.” R E C I T A L S WHEREAS, |
|
| October 2, 2020 |
Tax Matters Agreement between PDL BioPharma, Inc. and LENSAR, Inc. EX-10.2 Exhibit 10.2 TAX MATTERS AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND LENSAR, INC. DATED AS OF SEPTEMBER 30, 2020 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1 Section 1.1 General 1 Section 1.2 Reference; Interpretation 6 ARTICLE II. ALLOCATION OF TAX LIABILITIES 6 Section 2.1 General Rule 6 Section 2.2 General Allocation Principles 7 Section 2.3 Allocation Conventions 7 ARTICLE III. PREP |
|
| October 2, 2020 |
8-K 1 d98252d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2020 (September 30, 2020) LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-039473 32-0125724 (State or Other Jurisdi |
|
| September 15, 2020 |
CORRESP September 15, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 14, 2020 |
CORRESP 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1. |
|
| September 14, 2020 |
Form of Certificate of Common Stock EX-4.1 Exhibit 4.1 .ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK [GRAPHIC APPEARS HERE]PAR VALUE $.01 COMMON STOCK Certificate Number ZQ00000000 THIS CERTIFIES THAT is the owner of LENSAR, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr |
|
| September 14, 2020 |
2020 Employee Stock Purchase Plan EX-10.5 Exhibit 10.5 LENSAR, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this LENSAR, Inc. 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of LENSAR, Inc., a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pur |
|
| September 14, 2020 |
EX-10.12 Exhibit 10.12 INDUSTRIAL REAL ESTATE LEASE DISCOVERY TECH CENTER ORLANDO, FLORIDA by and between CHALLENGER-DISCOVERY, LLC, Landlord and LENSAR, INC., Tenant July 30, 2010 TABLE OF CONTENTS ARTICLE PAGE ARTICLE 1 BASIC TERMS 1 ARTICLE 2 PREMISES 3 ARTICLE 3 LEASE TERM 3 ARTICLE 4 RENT 4 ARTICLE 5 PROPERTY TAXES 6 ARTICLE 6 UTILITIES 6 ARTICLE 7 INSURANCE 7 ARTICLE 8 COMMON AREAS 10 ARTICL |
|
| September 14, 2020 |
Preliminary Information Statement of LENSAR, Inc., subject to completion, dated September 14, 2020 EX-99.1 Table of Contents Exhibit 99.1 PDL BioPharma, Inc. 932 Southwood Boulevard Incline Village, Nevada 89451 , 2020 Dear PDL Stockholder: I am pleased to report that the previously announced separation from PDL BioPharma, Inc. (“PDL”) of its majority-owned subsidiary, LENSAR, Inc. (“LENSAR”) and the distribution of all of the outstanding shares of common stock of LENSAR held by PDL on a pro ra |
|
| September 14, 2020 |
10-12B/A As filed with the Securities and Exchange Commission on September 14, 2020 File No. |
|
| August 26, 2020 |
Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Thomas R. Staab II EX-10.8 2800 DISCOVERY DRIVE ORLANDO, FL 32826 Exhibit 10.8 July 21, 2020 Thomas R. Staab, II c/o LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, FL 32826 Dear Thomas: You (the “Employee”) are a party to an employment letter (the “Original Letter”) dated April 28, 2020 with LENSAR, Inc. (the “Company” or “LENSAR”). The Board of Directors (the “Board”) of the Company desires to confirm the te |
|
| August 26, 2020 |
Form of Separation and Distribution Agreement between PDL BioPharma, Inc. and LENSAR, Inc. EX-2.1 Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND LENSAR, INC. DATED AS OF [●], 2020 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 2 Section 1.1 General 2 Section 1.2 Reference; Interpretation 9 Section 1.3 Tax Matters 9 ARTICLE II. THE SEPARATION 10 Section 2.1 Restructuring 10 Section 2.2 Transfer of LENSAR Assets and LENSAR Business; Assumption of LENSAR |
|
| August 26, 2020 |
Form of Indemnification Agreement between LENSAR, Inc. and its directors and officers EX-10.9 Exhibit 10.9 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [], 2020 between LENSAR, Inc., a Delaware corporation (the “Company”), and [name] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided with |
|
| August 26, 2020 |
EX-10.10 Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. CONFIDENTIAL INFORMATION EXCLUSIVE LICENSE AGREEMENT Between DOUG PATTON AND OPTHALMIC SYNERGIES, LLC and LENSAR, Inc. This Exclusive License Agreem |
|
| August 26, 2020 |
Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Alan Connaughton EX-10.7 2800 DISCOVERY DRIVE ORLANDO, FL 32826 Exhibit 10.7 July 21, 2020 Alan Connaughton c/o LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, FL 32826 Dear Alan: You (the “Employee”) are a party to an employment letter (the “Original Letter”) dated May 15, 2017 with LENSAR, Inc. (the “Company” or “LENSAR”). The Board of Directors (the “Board”) of the Company desires to confirm the terms of |
|
| August 26, 2020 |
Form of Restricted Stock Agreement pursuant to 2020 Incentive Award Plan EX-10.4.1 Exhibit 10.4.1 LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company has granted to the participant listed below (“Parti |
|
| August 26, 2020 |
10-12B As filed with the Securities and Exchange Commission on August 25, 2020 File No. |
|
| August 26, 2020 |
Form of Transition Services Agreement between PDL BioPharma, Inc. and LENSAR, Inc. EX-10.1 Exhibit 10.1 TRANSITION SERVICES AGREEMENT THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is made and entered into as of , 2020, by and between PDL BioPharma, Inc., a Delaware corporation (“PDL”) and LENSAR, Inc., a Delaware corporation (“LENSAR”). PDL and LENSAR are referred to herein individually as a “Party”, and collectively as the “Parties.” R E C I T A L S WHEREAS, PDL and LEN |
|
| August 26, 2020 |
Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Nicholas Curtis EX-10.6 2800 DISCOVERY DRIVE ORLANDO, FL 32826 Exhibit 10.6 July 21, 2020 Nicholas T. Curtis c/o LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, FL 32826 Dear Nick: You (the “Employee”) are a party to an employment letter (the “Original Letter”) dated May 15, 2017 with LENSAR, Inc. (the “Company” or “LENSAR”). The Board of Directors (the “Board”) of the Company desires to confirm the terms o |
|
| August 26, 2020 |
Development Agreement, dated January 29, 2020, by and between LENSAR, Inc. and Oertli Instrumente AG EX-10.11 Exhibit 10.11 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Development Agreement This Development Agreement (“Agreement”), is made and entered into, to be effective as of January 29, 2020 (the “Effective Dat |
|
| August 26, 2020 |
EX-10.12 Exhibit 10.12 INDUSTRIAL REAL ESTATE LEASE DISCOVERY TECH CENTER ORLANDO, FLORIDA by and between CHALLENGER-DISCOVERY, LLC, Landlord and LENSAR, INC., Tenant July 30, 2010 TABLE OF CONTENTS ARTICLE PAGE ARTICLE 1 BASIC TERMS 1 ARTICLE 2 PREMISES 3 ARTICLE 3 LEASE TERM 3 ARTICLE 4 RENT 4 ARTICLE 5 PROPERTY TAXES 6 ARTICLE 6 UTILITIES 6 ARTICLE 7 INSURANCE 7 ARTICLE 8 COMMON AREAS 10 ARTICL |
|
| August 26, 2020 |
Non-Employee Director Compensation Program EX-10.13 Exhibit 10.13 LENSAR, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of LENSAR, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2020 Incentive Award Plan (the “Equity Plan”) and sha |
|
| August 26, 2020 |
Form of Amended and Restated Certificate of Incorporation of LENSAR, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LENSAR, INC. LENSAR, INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is LENSAR, Inc. The Corporation was incorporated under the name LaserSoft Vision, Inc. by the filing of its |
|
| August 26, 2020 |
Preliminary Information Statement of LENSAR, Inc., subject to completion, dated August 25, 2020 EX-99.1 Table of Contents Exhibit 99.1 PDL BioPharma, Inc. 932 Southwood Boulevard Incline Village, Nevada 89451 , 2020 Dear PDL Stockholder: I am pleased to report that the previously announced separation from PDL BioPharma, Inc. (“PDL”) of its majority-owned subsidiary, LENSAR, Inc. (“LENSAR”) and the distribution of all of the outstanding shares of common stock of LENSAR held by PDL on a pro ra |
|
| August 26, 2020 |
EX-10.3 Exhibit 10.3 LENSAR, INC. PHANTOM STOCK PLAN The purpose of the LENSAR, Inc. Phantom Stock Plan is to promote the long-term financial interests and growth of LENSAR, Inc., a Delaware corporation (the “Company”), by attracting and retaining personnel with the training, experience and ability to enable them to make a substantial contribution to the success of the businesses of the Company an |
|
| August 26, 2020 |
Form of Amended and Restated Bylaws of LENSAR, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LENSAR, INC. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures for Business Brought before a Meeting 2 2.5 Advance Notice Procedures for No |
|
| August 26, 2020 |
EX-10.4 Exhibit 10.4 LENSAR, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| August 26, 2020 |
Form of Tax Matters Agreement between PDL BioPharma, Inc. and LENSAR, Inc. EX-10.2 Exhibit 10.2 TAX MATTERS AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND LENSAR, INC. DATED AS OF [ 🌑 ], 2020 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1 Section 1.1 General 1 Section 1.2 Reference; Interpretation 6 ARTICLE II. ALLOCATION OF TAX LIABILITIES 6 Section 2.1 General Rule 6 Section 2.2 General Allocation Principles 7 Section 2.3 Allocation Conventions 7 ARTICLE III. PREPARATIO |
|
| August 25, 2020 |
CORRESP 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1. |
|
| August 4, 2020 |
LENSAR, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. EX-10.4 Exhibit 10.4 LENSAR, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| August 4, 2020 |
DRS/A CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on August 4, 2020 File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12 (b) OR (g) OF THE SECURITIES EXCHANGE ACT OF |
|
| August 4, 2020 |
DRSLTR 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1. |
|
| August 4, 2020 |
LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE EX-10.4.1 Exhibit 10.4.1 LENSAR, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of LENSAR, Inc. (the “Company”). The Company has granted to the participant listed below (“Parti |
|
| August 4, 2020 |
LENSAR, INC. PHANTOM STOCK PLAN EX-10.3 Exhibit 10.3 LENSAR, INC. PHANTOM STOCK PLAN The purpose of the LENSAR, Inc. Phantom Stock Plan is to promote the long-term financial interests and growth of LENSAR, Inc., a Delaware corporation (the “Company”), by attracting and retaining personnel with the training, experience and ability to enable them to make a substantial contribution to the success of the businesses of the Company an |
|
| August 4, 2020 |
EX-10.10 Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. CONFIDENTIAL INFORMATION EXCLUSIVE LICENSE AGREEMENT Between DOUG PATTON AND OPTHALMIC SYNERGIES, LLC and LENSAR, Inc. This Exclusive License Agreem |
|
| August 4, 2020 |
CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 EX-99.1 Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 Exhibit 99.1 PDL BioPharma, Inc. 932 Southwood Boulevard Incline Village, Nevada 89451 , 2020 Dear PDL Stockholder: I am pleased to report that the previously announced separation from PDL BioPharma, Inc. (“PDL”) of its majority-owned subsidiary, LENSAR, Inc. (“LENSAR”) and the distribut |
|
| August 4, 2020 |
EX-10.11 Exhibit 10.11 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Development Agreement This Development Agreement (“Agreement”), is made and entered into, to be effective as of January 29, 2020 (the “Effective Dat |
|
| June 19, 2020 |
DRS CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on June 19, 2020 File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12 (b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 LENSAR, INC. (Exa |
|
| June 19, 2020 |
CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 EX-99.1 Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY LENSAR, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 Exhibit 99.1 PDL BioPharma, Inc. 932 Southwood Boulevard Incline Village, Nevada 89451 , 2020 Dear PDL Stockholder: I am pleased to report that the previously announced separation from PDL BioPharma, Inc. (“PDL”) of its majority-owned subsidiary, LENSAR, Inc. (“LENSAR”) and the distribut |
